下一代布鲁顿的氨酸激酶抑制剂-体外功效和选择性的特征
Robert Pulz1, Daniela Angst1, Bruno Cenni1
1Novartis BioMedical Research, Fabrikstrasse 2, 4056, Basel, Switzerland.
European journal of pharmacology
|May 22, 2025
概括
针对自身免疫和过敏的新型布鲁顿的氨酸激酶抑制剂 (BTKi) 在体外具有不同的结合性和选择性. 雷米布鲁丁尼布在共价抑制剂中表现出最强大和最快速的BTK抑制.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 对于B细胞受体和Fc受体信号传递至关重要,在自身免疫和过敏中起着关键作用.
- 一些具有不同结合方式 (共价-不可逆转,共价-可逆转,非共价可逆转) 的新型BTK抑制剂 (BTKi) 正在开发中,用于非瘤疾病.
研究的目的:
- 在相同的测定条件下描述和比较新型BTKi的体外功效和选择性.
- 评估不同BTKi类的结合动力学和细胞通路抑制.
主要方法:
- 在体外评估人类血液BTK对共价BTKi的结合.
- 细胞BTK通路抑制测定在人类血液B细胞和基细胞中.
- 基因组范围内的激酶选择性选和结合亲和度量化.
主要成果:
- 共价BTKi表现出时间和度依赖的BTK结合,而雷米布鲁丁尼布显示出最高的强度和最快的开始.
- 细胞BTK抑制与对共价BTKi的BTK结合相关;雷米布鲁丁尼布保持了抑制,而费内布鲁丁尼布显示出快速冲洗.
- BTKi选择性排名 (最多到最少选择性):雷米布鲁丁尼布,费内布鲁丁尼布,埃沃布鲁丁尼布,奥雷拉布鲁丁尼布,里尔扎布鲁丁尼布和托莱布鲁丁尼布.
结论:
- 下一代BTKi在目标参与度和选择性概况中显示出显著的体外差异.
- 这些独特的特征可能会影响它们在治疗自身免疫和过敏性疾病的治疗疗效和安全性.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


